About Avience Biomedicals IPO
Incorporated in June 2024, Avience Biomedicals Ltd. is an ISO-certified healthcare company engaged in the manufacturing, supply, export, distribution, and trading of diagnostic products and medical equipment. The company operates in the fast-growing biotechnology, genomics, and in-vitro diagnostics (IVD) space, catering exclusively to B2B and B2G customers.
Over time, Avience has expanded beyond rapid diagnostic kits to build a diversified portfolio of diagnostic solutions serving pathology laboratories, microbiology labs, hospitals, research institutions, and healthcare providers across India and overseas markets. Its manufacturing facility is located in Noida, Uttar Pradesh, supporting the production and supply of a wide range of healthcare products.
The company's offerings include rapid test kits for diseases such as dengue, malaria, and syphilis; molecular diagnostic solutions including RT-qPCR-based COVID-19 detection kits; biochemistry analyzers and reagents; hematology analyzers; oxygen concentrators; viral transport media; and other medical devices. Alongside manufacturing, Avience also acts as a distributor and trader of diagnostic equipment, enabling it to address diverse customer requirements through a single platform.
Workforce
As of January 31, 2026, the company had a workforce of 75 permanent employees and 33 contractual employees, supporting its manufacturing, quality control, sales, and operational activities.
Avience Biomedicals IPO Subscription Breakdown
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 49% | 7,12,362 crores |
| Non-Institutional Investors (NIIs) | 15% | 2,18,070 crores |
| Retail Individual Investors (RIIs) | 36% | 5,23,368 crores |
Avience Biomedicals IPO Financial Highlights
No Data Found
Avience Biomedicals IPO Strengths & Weaknesses
Experienced leadership team with expertise in diagnostics and healthcare solutions.
Diversified product portfolio spanning rapid test kits molecular diagnostics analyzers reagents and medical devices.
Strong distribution network across India with an expanding international presence.
Focus on delivering cost-effective and accessible diagnostic solutions.
ISO-certified operations supported by stringent quality control and regulatory compliance processes.
Presence across multiple segments of the IVD and diagnostics value chain.
Avience Biomedicals IPO Important Dates & Issue Details
| Allotment Date | Listing Date | Refund Date |
|---|---|---|
| 23 Jun '26 | -- | 24 Jun '26 |
| Issue Composition: | |
|---|---|
| Face Value | ₹10 per share |
| Total Issue Size | 14,53,800 shares (aggregating up to ₹2,49,600 crores) |
| Fresh Issue | 1,37,160 shares (aggregating up to ₹13,71,600 crores) |
| Offer for Sale | 0 shares of ₹10 (aggregating up to To be announced) |
| Issue Type | Book building |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 92.85 shares |
| Post-Issue Shareholding | 0 shares |
Avience Biomedicals IPO Lot Size and Investment Details
| Minimum Lot Size | 600 shares |
| Maximum Lot Size (Retail) | 2,400 shares |
The lot size of Avience Biomedicals ipo has been designed to ensure broad participation while maintaining optimal price discovery.
How to Apply for Avience Biomedicals IPO
- Log in to your Choice account
- Select IPO
- Enter the number of lots and your price
- Verify UPI ID
- Complete the transaction on your UPI app
Avience Biomedicals IPO Contact & Registrar Details
Contact Details
Address
C-11 Block- C Community Centre New Delhi
Phone Number
Website
Registrar Details
Registrar Name
Skyline Financial Services Pvt.Ltd.
Phone Number
Optivalue Tek Consulting Ltd IPO Lead Manager(s)
| Book Running Lead Manager(s) |
|---|
| Fintellectual Corporate Advisors Pvt Ltd |